(RTTNews) - Merck & Co. Inc. (MRK) on Tuesday announced the results from two pivotal Phase 3 trials, COUGH-1 and COUGH-2, evaluating the efficacy and safety of gefapixant (MK-7264) for the potential ...
Merck announced topline data from 2 ongoing pivotal phase 3 trials (COUGH-1 and COUGH-2) for gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough. Merck announced topline ...
Physicians may be able to better identify patients with chronic cough using the combination of 2 coughing tests. Researchers found the combination of the cough suppression test and the cough challenge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results